Although, in principle, these β-glucan-based drugs are used in combination with other chemical anti-tumor drugs, it has been demonstrated that β-glucans enhance the anti-tumor activity of chemical anti-tumor drugs through the activation of immunity to eliminate tumor cells in clinical trials. Here, PPIB is linked to neoplasm.